Follow
Matthew Austin
Matthew Austin
Statistician, Amgen
Verified email at amgen.com
Title
Cited by
Cited by
Year
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
SR Cummings, JS Martin, MR McClung, ES Siris, R Eastell, IR Reid, ...
New England Journal of Medicine 361 (8), 756-765, 2009
39962009
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 …
JP Brown, RL Prince, C Deal, RR Recker, DP Kiel, LH De Gregorio, ...
Journal of bone and mineral research 24 (1), 153-161, 2009
7902009
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized …
PD Miller, MA Bolognese, EM Lewiecki, MR McClung, B Ding, M Austin, ...
Bone 43 (2), 222-229, 2008
6662008
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension
S Papapoulos, R Chapurlat, C Libanati, ML Brandi, JP Brown, ...
Journal of Bone and Mineral Research 27 (3), 694-701, 2012
4552012
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
M Austin, YC Yang, E Vittinghoff, S Adami, S Boonen, DC Bauer, ...
Journal of Bone and Mineral Research 27 (3), 687-693, 2012
1822012
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial
JP Brown, C Roux, O Törring, PR Ho, JE Beck Jensen, N Gilchrist, ...
Journal of Bone and Mineral Research 28 (4), 746-752, 2013
1752013
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
EV McCloskey, H Johansson, A Oden, M Austin, E Siris, A Wang, ...
Journal of Bone and Mineral Research 27 (7), 1480-1486, 2012
1612012
Differing effects of denosumab and alendronate on cortical and trabecular bone
RM Zebaze, C Libanati, M Austin, A Ghasem-Zadeh, DA Hanley, ...
Bone 59, 173-179, 2014
1572014
Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
M Hedenus, J Vansteenkiste, D Kotasek, M Austin, RG Amado
Journal of clinical oncology 23 (28), 6941-6948, 2005
962005
Amg Bone Loss Study Group: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting …
PD Miller, MA Bolognese, EM Lewiecki, MR McClung, B Ding, M Austin, ...
Bone 43 (2), 222-229, 2008
562008
The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel
EA Bower, JL Moore, M Moss, KA Selby, M Austin, S Meeves
Aviation, space, and environmental medicine 74 (2), 145-152, 2003
482003
Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis
C Bugos
Diabetes Res Clin Pract 50, S47, 2000
442000
The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy
E Seeman, C Libanati, M Austin, R Chapurlat, SK Boyd, R Zebaze, ...
J Bone Miner Res 26 (Suppl 1), S22, 2011
232011
Centralized statistical monitoring of clinical trial enrollment performance
V Anisimov, M Austin
Communications in Statistics: Case Studies, Data Analysis and Applications 6 …, 2020
102020
Effect of densoumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level
JP Brown, C Deal, LH de Gregorio, LC Hofbauer, H Wang, M Austin, ...
JOURNAL OF BONE AND MINERAL RESEARCH 23, S80-S80, 2008
72008
DENOSUMAB REDUCES THE RISK OF CLINICAL OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN, PARTICULARLY IN THOSE WITH MODERATE TO HIGH FRACTURE RISK AS ASSESSED WITH FRAX (R)
E McCloskey, M Lewiecki, J Kanis, H Johansson, A Oden, M Austin, ...
OSTEOPOROSIS INTERNATIONAL 22, 103-103, 2011
52011
Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy
RE Smith Jr, JA Glaspy, NS Tchekmedyian, MD Austin, JD Kallich
Supportive cancer therapy 1 (1), 49-54, 2003
52003
Effects of single dose fexofenadine, diphenhydramine, and placebo on cognitive and psychomotor performance in naval flight personnel in a double‐blind, crossover randomised study
E Bower, J Moore, M Moss, K Selby, M Austin, S Meeves
Allergy 55 (Suppl 63), 912, 2000
52000
Forecasting and optimizing patient enrolment in clinical trials under various restrictions
V Anisimov, M Austin
International Conference on Stochastic Processes and Algebraic Structures …, 2019
42019
Graphical analyses of clinical trial safety data
H Ma, K Zhou, A Xia, M Austin, G Li, M O’Connell
Joint statistical meeting-statistical computing and statistical graphics …, 2007
42007
The system can't perform the operation now. Try again later.
Articles 1–20